contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Analyst

Antti Siltanen

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

itus on antaa yrityksille mahdollisuus pysyä euroopassa. Onko 2,5 miljoonaa euroa syy lähteä euroopasta?"  If the goal is to stay, and the author asks if 2.5m is a reason to leave…  It means “Is 2.5m [so little that it provides] a reason to leave?”  Yes, “Is €2.5 million a reason to leave Europe?” is the most accurate translation of the words used. It implies the pittance is an

Indeed. It’s hard to tell from the short press release what form the funding will take. It does mention that the €10 billion foundation is based on a €3.5 billion debt financing pot from the European Investment Bank. If they continue on that path and Faron gets a slice of it, then more dilution is likely on the way. There’s a fair amount of politics involved here, as the Commission wants to keep promising biotechs away from the US capital markets. So, this is the EU’s response to Trump’s “America First” ideology, and when you consider that the Health Secretary there is a vaccine critic fond of conspiracy theories, you can understand the EU’s reaction. On this side of the Atlantic, they want to keep medical research as a protocol that strictly follows scientific rules. Perhaps there’s also an unspoken hope that some biotechs might even submit their first marketing authorization application to the EMA during the registration phase, so that Europe would be the first market for the new drug.

Well, then there’s still almost €10B left for others to share. I wouldn’t be on cloud nine just yet, but if one of the most promising biotechs only gets crumbs, then what will be left for the next 1,000 to share? The top ten should get enough per case to have an impact – right? And if impact is the goal, €10m for Faron only buys 3 more months… so no impact. Time will tell, but that “soon = 2026” is about 12 days away. Let’s hope for the best – although a pessimist won’t be disappointed by €2.5M

These EU-funded projects are running all the time. Faron received €2.5m for MATINS. There is no non-dilutive funding for an entire trial coming. It smells like Copium on the forum again.

It’s not quite clear from the EU’s announcement whether the intention is to provide funding directly to biotechs (and if so, is it low-cost debt financing or some other financing model)? Or are the billions being directed to European venture capital funds specializing in the biotech sector, which then pick promising biotechs for their portfolios. Regardless, it’s clear that Faron’s clinical evidence is of such a standard that, by all logic, funding should be obtainable from this pot. If the EU lends a helping hand, then the long-awaited partnership deal will likely be delayed until the stage where Bex has marketing authorization and the drug needs to be marketed and manufactured in large quantities.

Faron’s 4th largest shareholder is an entity called The European Innovation Council Equity Fund (EIC). Somehow Europe and the EU always let us down, but could there be real support for an important cause this time? Funding for small companies to the point where large European BPs can smoothly take over from there.

Well now. Would it be too much speculation if Faron had slowed down the closing of the deal a bit in pursuit of these subsidies? The way the FDA & US administration are treating Novo Nordisk now (blocking the acquisition and most recently the cat hair allegations related to a few drug batches) has hopefully also prompted the EU to act. Additionally, Trump’s threatened drug tariffs and forced price reductions (e.g., Pfizer) are clear signs that something needs to be done in Europe. If Faron is truly among the top 10 most promising biotechs in Europe (mentioned earlier in the thread), this means that support & funding are coming, if they’ve had the sense to apply for it. I’m left wondering when and how (at what stage) that could be announced to the stock exchange – if realized, a great pilot project whose impact would be, to put it mildly, “staggering”. GoFaronGO

Faron Pharmaceuticals

Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk ...

<p>Faron Pharmaceuticals is a clinical stage biopharmaceutical company whose three drug candidates relate to the modulation of immune system or inflammatory response. Faron is a very high-risk investment as drug development requires frontloaded investments in research, while the success of commercialization is very uncertain. If the drug candidates enter the market, the invested capital can be multiplied. However, failure of drug development is frequent and, in that case, the invested capital may be partially or totally lost. We believe the share provides sufficient expected return to counterbalance the high risk. The share is suitable for a long-term investor that tolerates high risk as part of a well-diversified portfolio. A person investing in Faron must also be prepared for share issues.</p> 

	2021	22e	23e
Revenue	0.0	0.0	0.0
growth-%
EBIT (adj.)	-21.1	-22.0	-0.8
EBIT-% (adj.)	-527,700.0 %	-550,000.0 %	-19,500.0 %
EPS (adj.)	-0.40	-0.40	-0.02
Dividend	0.00	0.00	0.00
Dividend %
P/E (adj.)	neg.	neg.	neg.
EV/EBITDA	neg.	neg.	neg.

Risky investment with huge potential

Login required

Key Estimate Figures08.08.2022

Forum discussions